ArticleJournal of clinical laboratory analysis2018
Identification of potential tumor-educated platelets RNA biomarkers in non-small-cell lung cancer by integrated bioinformatical analysis.
Article in Journal of clinical laboratory analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Utilization of TEP miRNAs in tumor proliferation, diagnostic evaluation, therapeutic intervention, and prognostic assessment.Molecular biology reports · 2025Review
- Platelet-Derived circRNAs hsa_circ_0004771 and hsa_circ_0019120 Differentially Expressed in Colorectal Cancer and Polyps.Reports of biochemistry & molecular biology · 2024Article
- Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring.Molecular cancer · 2024Review
- Article
- Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. "Re-discovering the neglected biosources of the liquid biopsy family".The journal of liquid biopsy · 2024Review
- Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.Frontiers in molecular biosciences · 2024Review
- Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA.NAR cancer · 2022Article
- Construction and validation of a novel prediction system for detection of overall survival in lung cancer patients.World journal of clinical cases · 2022Article
- Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.Molecular cancer · 2022Review
- Selection and Validation of Reference Genes for Pan-Cancer in Platelets Based on RNA-Sequence Data.Frontiers in genetics · 2022Article
- Tumor-Educated Platelets: A Review of Current and Potential Applications in Solid Tumors.Cureus · 2021Review
- Review
- The Role of Circulating Biomarkers in Lung Cancer.Frontiers in oncology · 2021Review
- Integrative Transcriptome-Wide Analyses Uncover Novel Risk-Associated MicroRNAs in Hormone-Dependent Cancers.Frontiers in genetics · 2021Article
- Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies.Frontiers in oncology · 2021Review
- Pancreatic Cancer and Platelets Crosstalk: A Potential Biomarker and Target.Frontiers in cell and developmental biology · 2021Review
- Circular RNA SMARCA5 may serve as a tumor suppressor in non-small cell lung cancer.Journal of clinical laboratory analysis · 2020Article
- The biogenesis and biological functions of circular RNAs and their molecular diagnostic values in cancers.Journal of clinical laboratory analysis · 2020Article
- Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data.International journal of oncology · 2019Article
- Identification of potential tumor-educated platelets RNA biomarkers in non-small-cell lung cancer by integrated bioinformatical analysis.Journal of clinical laboratory analysis · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPlatelets have emerged as key players in tumorigenesis and tumor progression. Tumor-educated platelet (TEP) RNA profile has the potential to diagnose non-small-cell lung cancer (NSCLC). The objective of this study was to identify potential TEP RNA biomarkers for the diagnosis of NSCLC and to explore the mechanisms in alternations of TEP RNA profile.
methodsThe RNA-seq datasets GSE68086 and GSE89843 were downloaded from Gene Expression Omnibus DataSets (GEO DataSets). Then, the functional enrichment of the differentially expressed mRNAs was analyzed by the Database for Annotation Visualization and Integrated Discovery (DAVID). The miRNAs which regulated the differential mRNAs and the target mRNAs of miRNAs were identified by miRanda and miRDB. Then, the miRNA-mRNA regulatory network was visualized via Cytoscape software.
resultsTwenty consistently altered mRNAs (2 up-regulated and 18 down-regulated) were identified from the two GSE datasets, and they were significantly enriched in several biological processes, including transport and establishment of localization. Twenty identical miRNAs were found between exosomal miRNA-seq dataset and 229 miRNAs that regulated 20 consistently differential mRNAs in platelets. We also analyzed 13 spliceosomal mRNAs and their miRNA predictions; there were 27 common miRNAs between 206 differential exosomal miRNAs and 338 miRNAs that regulated 13 distinct spliceosomal mRNAs.
conclusionThis study identified 20 potential TEP RNA biomarkers in NSCLC for diagnosis by integrated bioinformatical analysis, and alternations in TEP RNA profile may be related to the post-transcriptional regulation and the splicing metabolisms of spliceosome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.